

Mariana Oncology

Reskinned Website Options

November 7, 2022



Homepage Option 1






[Our Vision](#)[Discover Our Science](#)[Work with Us](#)[Explore What's New](#)

We are now Mariana Oncology

LEARN MORE



We're Mariana Oncology

We create medicines to treat cancer's toughest tumors by harnessing the power of precisely delivered radiation and preserving life through a better standard of care.



OUR VISION

Mariana Oncology envisions a world where cancer care is transformed by precision radiopharmaceuticals and a future in which these drugs are increasingly incorporated into mainstream treatment.



DISCOVER OUR SCIENCE

Mariana Oncology treats cancer's toughest tumors by harnessing the power of precisely delivered radiation. Through safe, effective, and highly-targeted radiopharmaceuticals for solid cancers, we're preserving lives through a better standard of care.



WORK WITH US

Too often, organizations focus on their products, not their people. Your talent deserves to be nurtured and developed, so you can thrive and enjoy where you work. We'll provide you with unique opportunities you'll rarely get anywhere else.



EXPLORE WHAT'S NEW

We're taking integrated approaches to developing and delivering our unique portfolio of treatments focused on minimizing trauma to our patients.



[Our Vision](#)[Discover Our Science](#)[Work with Us](#)[Explore What's New](#)

We are now Mariana Oncology

LEARN MORE



Homepage Option 2a





[Our Vision](#)[Discover Our Science](#)[Work with Us](#)[Explore What's New](#)

Big Changes to Cancer Treatment Are Coming

LEARN MORE



OUR VISION

Mariana Oncology envisions a world where cancer care is transformed by precision radiopharmaceuticals and a future in which these drugs are increasingly incorporated into mainstream treatment.



DISCOVER OUR SCIENCE

Mariana Oncology treats cancer's toughest tumors by harnessing the power of precisely delivered radiation. Through safe, effective, and highly-targeted radiopharmaceuticals for solid cancers, we're preserving lives through a better standard of care.



WORK WITH US

Too often, organizations focus on their products, not their people. Your talent deserves to be nurtured and developed, so you can thrive and enjoy where you work. We'll provide you with unique opportunities you'll rarely get anywhere else.



EXPLORE WHAT'S NEW

We're taking integrated approaches to developing and delivering our unique portfolio of treatments focused on minimizing trauma to our patients.



[Our Vision](#)[Discover Our Science](#)[Work with Us](#)[Explore What's New](#)



Big Changes to Cancer Treatment Are Coming

LEARN MORE





3

Homepage Option 2b




Homepage Option 2



Potential visual direction for the new site



Team Page Options




Team Page Option 1



[Our Vision](#) [Discover Our Science](#) [Work with Us](#) [Explore What's New](#)

Our Team



Malik Faheem, PhD
Officer Title




Team Page Option 2



[Our Vision](#) [Discover Our Science](#) [Work with Us](#) [Explore What's New](#)

Our Team



Malik Faheem, PhD
Officer Title



Team Page Option 3



[Our Vision](#) [Discover Our Science](#) [Work with Us](#) [Explore What's New](#)

Our Team



Malik Faheem, PhD
Officer Title



Team Page Options



Management Team

iPondr LEADERSHIP

Alonso Ricardo, PhD

Alonso serves as the chief scientific officer of Curie Therapeutics Inc. Before joining Curie, Alonso was an entrepreneur-in-residence at RA Capital Management.


Prior to this, Alonso was chief technology and innovation officer at Ra Pharma (NASDAQ: RARX) until its acquisition by UCB Pharma. Alonso has more than a decade of drug discovery and development experience leading scientific programs across multiple therapeutic programs including immunology, metabolic diseases, and oncology. While at Ra Pharma, Alonso led the discovery and early development of several experimental drugs, including Zilucoplan an immune modulator peptide currently being evaluated in several Phase 2/3 trials and MK-0616, a first in class, orally available peptide targeting PCSK9. Alonso was formerly a professor at the Universidad de los Andes in Bogota, Colombia, and a Howard Hughes Medical Institute Fellow at Harvard University. He obtained his Ph.D. in chemistry from the University of Florida and was a postdoctoral fellow at the Foundation for Applied Molecular Evolution, Massachusetts General Hospital and Harvard University.

In one of the new colors, of course!

Next Steps



- 1 Sign-off on direction.
- 2 Review copy (tweaked for tone, only).
- 3 We get to work.



+1-774-260-5560



douglas@spencerbrenneman.com



@DouglasWSpencer | SB_Branding



douglasspencer



spencerbrenneman.com

Spencer Brennenman, LLC

Our mission is to help
those who help us all.

Spencer Brennenman is made up of a virtual team of strategic and passionate thinkers and creatives who work together to match the skill sets or experiences to the clients we serve. For us, working virtually is a lifestyle choice. It allows us to do what we do best and work with organizations that truly inspire us.



Therapy